Expanding Bevacizumab-Erlotinib Therapy Through Fumarate Hydratase Deficiency Screening and Drug Target Pathway Analysis in Papillary Morphology Metastatic Renal Cell Carcinoma

European Urology · Published 2026-06-01 · DOI 10.1016/j.eururo.2026.04.026

Authors (6)

Javier de Nicolás-Hernández, Carlos Valdivia, Alicia Arenas, Miguel A. Zaballos, Mercedes Robledo, Cristina Rodríguez-Antona

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Nicolás-Hernández, J., Valdivia, C., Arenas, A., et al. (2026). Expanding Bevacizumab-Erlotinib Therapy Through Fumarate Hydratase Deficiency Screening and Drug Target Pathway Analysis in Papillary Morphology Metastatic Renal Cell Carcinoma. European Urology. https://doi.org/10.1016/j.eururo.2026.04.026

Related articles